908 Devices Names Kevin Hrusovsky, 30-year Biotechnology Veteran and Founder of Powering Precision Health, as Chairman of its Board of Directors

Rhea-AI Summary

908 Devices announced the appointment of Kevin Hrusovsky as Chairman of its Board of Directors. Hrusovsky, a veteran in biotechnology and CEO of Quanterix (NASDAQ: QTRX), brings extensive experience in commercializing disruptive healthcare technologies. His leadership is expected to bolster 908 Devices’ mission of democratizing mass spectrometry for critical applications in life sciences, bioprocessing, and forensics. Hrusovsky's commitment to transforming healthcare through advanced analytical tools positions the company well at a pivotal moment for next-gen proteomics.

Positive

• Kevin Hrusovsky's extensive experience is expected to enhance leadership at 908 Devices.
• The company's focus on democratizing mass spectrometry aligns with current healthcare needs.
• Hrusovsky's position may attract investment and collaboration opportunities, benefiting growth.

Negative

• None.

BOSTON, Oct. 30, 2020 /PRNewswire/ -- 908 Devices, a pioneer of purpose-built handheld and desktop Mass Spec devices for chemical and biomolecular analysis, today announced the appointment of Kevin Hrusovsky as the Chairman of its Board of Directors. Mr. Hrusovsky, who has served on the 908 Devices Board of Directors since 2013, is a biotech entrepreneur and healthcare visionary with a passion for revolutionizing healthcare and a proven track record of commercializing disruptive technologies.  

"Our devices are used by our customers who need answers quickly, at the point-of-need to interrogate the unknown-and-invisible and provide actionable answers to address some of the most critical problems in life sciences research, bioprocessing, industrial biotech, and forensics." said Dr. Kevin J. Knopp, CEO and Co-Founder of 908 Devices. "Kevin Hrusovsky's deep knowledge and experience are incredibly additive as we democratize laboratory Mass Spectrometry instruments with our simple handheld and desktop devices."

"There has never been a more important time in science to harness advanced analytical tools," said Mr. Hrusovsky. "I'm honored to be named Chairman and committed to supporting technologies that accelerate outcomes and disrupt healthcare. Kevin Knopp and the 908 Devices team are democratizing Mass Spectrometry at an important inflection point for next generation Proteomics and its promise to revolutionize healthcare."

Kevin Hrusovsky currently serves as the Chairman, CEO and President of Quanterix (NASDAQ: QTRX), a company digitizing biomarker analysis to advance precision health. He is also the founder of Powering Precision Health (PPH) foundation, a non-profit global think tank composed of the industry's top medical, research and financial experts. Through his non-profit network and the power of Quanterix's disruptive Simoa technology, Mr. Hrusovsky is accelerating critical advances across neurology, oncology, infectious disease, cardiology, and inflammation.

A dynamic and respected thought leader, Hrusovsky is regularly sought after by mainstream media, including CBS, NBC, CNN, and other major news outlets to speak on the promise of precision health to diagnose diseases before symptoms even occur. Most recently, Mr. Hrusovsky spearheaded a newly formed Emergency COVID-19 Diagnostic & Drug PPH Advisory Panel that aims to enhance global understanding of COVID-19, including the innate and adaptive immune response to drive earlier intervention in the disease cascade, deliver more targeted therapeutic responses, and accelerate development of emerging drugs and vaccines.

About 908 Devices
We make point-of-need-devices ranging from rugged, handheld chemical detection tools to compact, tiny footprint desktop analyzers. These uncomplicated purpose-built devices provide users with the power to redefine their workflows by getting actionable answers at the point of need. Our devices are being used for critical applications across the globe in life science research, bioprocessing, industrial biotech, forensics and adjacent markets. 908 Devices is headquartered in the heart of Boston, where we research, design and manufacture innovative products that bring together high-pressure mass spectrometry™ (HPMS), microfluidic separations, software automation, and machine learning.  For more information, visit www.908devices.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/908-devices-names-kevin-hrusovsky-30-year-biotechnology-veteran-and-founder-of-powering-precision-health-as-chairman-of-its-board-of-directors-301164162.html

SOURCE 908 Devices

FAQ

What does the appointment of Kevin Hrusovsky as Chairman mean for Quanterix (NASDAQ: QTRX)?

Kevin Hrusovsky's appointment as Chairman may strengthen Quanterix's leadership and strategic direction in precision health.

How will Kevin Hrusovsky's experience benefit 908 Devices?

Hrusovsky's background in biotechnology and healthcare innovation is likely to provide valuable insights and strategic advantages to 908 Devices.

What is the significance of Hrusovsky's role in advancing mass spectrometry at 908 Devices?

Hrusovsky's leadership is crucial for 908 Devices as it seeks to democratize mass spectrometry, making advanced analytics accessible in critical applications.

What are the expected impacts of Hrusovsky's leadership on the healthcare industry?

His leadership could accelerate the adoption of innovative diagnostic tools and enhance the understanding of diseases, leading to improved healthcare outcomes.